Navigation Links
Researchers Evaluate Computer-based Treatment for People with Schizophrenia
Date:6/27/2012

SAN FRANCISCO, June 27, 2012 /PRNewswire/ -- Researchers at San Francisco-based Brain Plasticity, Inc. (BPI) have begun a multi-center study to evaluate the effects of a computerized, brain-plasticity-based program designed to address the cognitive issues associated with schizophrenia.  The clinical trial, e-CAeSAR (Evaluation of a Cognitively Adaptive e-treatment in Schizophrenia-diagnosed Adults:  A Remediation-based Approach), is being funded by the National Institute of Mental Health (NIMH) and will be conducted at eleven research centers in the U.S. in collaboration with experienced investigators from the Schizophrenia Trials Network (STN).

Cognitive impairment is a devastating component of schizophrenia that affects virtually all persons who are diagnosed.  The NIMH estimates that nearly 40 percent ($44 billion) of schizophrenia's total cost involves lost time from work for patients and care providers, and places high demands on social services.  This makes schizophrenia the most costly mental illness in the United States.

The "e-CAeSAR" trial is the first time neuroscientists will work with U.S. Food and Drug Administration representatives to evaluate Brain Plasticity's program.  Pharmaceutical companies have tested drugs in development to alleviate the cognitive symptoms of schizophrenia; thus far none have been FDA-approved as efficacious. 

"Cognitive impairment in schizophrenia sorely needs attention, yet there are no FDA-approved treatments for this devastating aspect of the illness," notes Dr. Richard Keefe of the Schizophrenia Trials Network (STN).  These cognitive impairments can limit the ability of persons with schizophrenia to process new information accurately and quickly, make effective decisions and remember key information.  Coupled together, these symptoms can severely impair patients' abilities to perform everyday activities, live independently, gain employment and sustain social relationships. It is commonly believed that the most significant symptoms of schizophrenia are delusions and/or hallucinations, yet these represent only a fraction of the symptoms.

"We are honored to work with world-renowned researchers who are part of the Schizophrenia Trials Network.  We hope that our efforts encourage other scientists to develop and study new cognitive treatments to support persons with schizophrenia and their families," states BPI Chief Operating Officer Dr. Henry Mahncke.

"We are excited to participate in this long-awaited, much-needed seminal trial of cognitive remediation for individuals with schizophrenia. Cognitive remediation is a potential breakthrough treatment that along with more traditional pharmaceutical and psychotherapeutic modalities may significantly impact the lives of those living with schizophrenia, their families and society as a whole, said Jennifer Hoblyn, MD, MPH, who directs Inpatient Mental Health Services at the Veterans Affairs Medical Center in Palo Alto, CA., an investigator in the e-CAeSAR study. 

About Brain Plasticity Incorporated

Brain Plasticity, Inc., was founded in 2009 to support the rapid development and evaluation of innovative neuroscience-based brain health solutions. For more information, visit www.brainplasticity.com or contact Henry Mahncke, PhD, at 415.394.3107.

Media Contact:

Peggy Jara

Harden Communications Partners

510-635-4150

pjara@hardenpartners.com


'/>"/>
SOURCE Brain Plasticity, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Rethinking Research Ethics: Carnegie Mellon and McGill Researchers Challenge Post-marketing Trial Practices
2. Van Andel Institute Researchers Find Potential Drug Target For Aggressive Form Of Lymphoma
3. EvaluatePharma Names Debbie Paul CEO, Americas to Lead Growth in Key Region
4. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
5. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
6. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
7. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
8. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
9. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
10. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
11. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions ... initiated cultivation and processing operations at its production facility, and opened its first ... is the manufacturer of a complete system of proactive air and surface purification ...
(Date:6/24/2016)... ... , ... National recruitment firm Slone Partners is pleased to announce ... experience, as Vice President of North American Capital Sales at HTG Molecular . ... sales team in the commercialization of the HTG EdgeSeq system and associated reagents in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, MTI-GlobalStem, a provider ... and other difficult to transfect cells, announces its launch of the PluriQ™ G9™ ... Editing System is a complete system for culturing and transfecting human pluripotent ...
Breaking Medicine News(10 mins):